Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
SynopsisS

Can NSAIDs contribute to Alzheimer's disease?

David Secko
CMAJ June 21, 2005 172 (13) 1677; DOI: https://doi.org/10.1503/cmaj.050601
David Secko
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2005 CMA Media Inc. or its licensors

Several years ago it was discovered that some NSAIDs lower the levels of amyloid β peptide (Aβ). This peptide is a key component of neuritic plaques, which, along with neurofibrillary tangles and cerebral atrophy, are a pathologic hallmark of Alzheimer's disease. Not all NSAIDs produce this result, however, and new research reveals that some cyclooxygenase-2 (COX-2) inhibitors actually increase the production of Aβ, an effect comparable to that of mutations thought to cause Alzheimer's disease.1

Figure1

Figure. Photo by: Photo.com

There are several forms of Aβ;the one with 42 amino acids (Aβ42) is the insoluble form found in neuritic plaques. The deposition of Aβ42 is thought to play an important role in the cascade of events leading to the formation of neurofibrillary tangles and the eventual degeneration of neurons. The production of Aβ42 is catalyzed by β- and γ-secretases. In 2001, Weggen and colleagues found that the NSAIDs ibuprofen, indomethacin and sulindac sulfide decrease the levels of Aβ42 in cells, in some cases by as much as 80%.2 This decrease appears not to be due to an effect on cyclooxygenase, the primary target of NSAIDs. Instead, these drugs appear to modulate the ability of γ-secretase to produce Aβ42.

The results of a number of epidemiological studies that preceded the study by Weggen and colleagues suggested that people using NSAIDs had a reduced incidence of Alzheimer's disease. This led to speculation that NSAIDs may aid in preventing this disease. However, clinical trials with rofecoxib and naproxen showed no benefit. A prevention trial for Alzheimer's disease using celecoxib was recently halted because COX-2 inhibitors were coming under fire for increasing the risk of adverse cardiovascular events.3

Mimicking Alzheimer's disease

In a recent study, Kukar and colleagues tested over 300 compounds, including COX-2 selective NSAIDs, NSAID derivatives and several novel compounds, with the goal of finding drugs that had little effect on cyclooxygenase but decreased the production of Aβ42.1 They exposed cultured H4 neuroglioma cells to various drugs and measured production of Aβ.

Their results were surprising. Although they discovered that one NSAID, R-flurbiprofen, lacked cyclooxygenase activity and reduced Aβ42 levels, many of the COX-2 inhibitors, including tilmacoxib and valdecoxib, increased the production of Aβ42. In particular, celecoxib raised Aβ42 levels by almost 200%. Rofecoxib and lumiracoxib only slightly influenced Aβ42 levels, even at high doses. The COX-2 selective NSAIDs appeared to exert their effects on Aβ42 production by targeting γ-secretase. This is similar to the mechanism by which autosomal dominant mutations linked to Alzheimer's disease are known to function.

NSAIDs are not the only class of drug that affects Aβ42 production. Fenofibrate, a lipid-lowering drug, increased the Aβ42 levels in cultured H4 cells by over 300% in a dose-dependent fashion. In contrast, fenofibric acid, the active metabolite of fenofibrate, did not raise Aβ42 levels, which suggests that the effect was specific to the drug.

The clinical implications of these findings are not clear, as the authors point out.1 In particular, it is uncertain whether celecoxib and the other drugs used in the study have the same effects in the human brain as they did in the mouse model used in the study. If they do, it is conceivable that they may have an impact on the pathology of Alzheimer's disease, which raises several issues for future study. The in vivo effects of COX-2 inhibitors on Aβ42 levels and subsequent neuritic plaque formation need to be ascertained. An understanding of how these NSAIDs modulate the activity of γ-secretase may one day contribute to the design of drugs that inhibit the production of Aβ.3 Finally, whether the drug-induced alteration of Aβ42 levels is a new risk factor for Alzheimer's disease needs further research.

References

  1. 1.↵
    Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 2005;11(6):545-50.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;414(6860):212-6.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Wyss-Coray T. Killing pain, killing neurons? Nat Med 2005;11(5):472-3.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 172 (13)
CMAJ
Vol. 172, Issue 13
21 Jun 2005
  • Table of Contents
  • Index by author

Article tools

Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Can NSAIDs contribute to Alzheimer's disease?
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Can NSAIDs contribute to Alzheimer's disease?
David Secko
CMAJ Jun 2005, 172 (13) 1677; DOI: 10.1503/cmaj.050601

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Can NSAIDs contribute to Alzheimer's disease?
David Secko
CMAJ Jun 2005, 172 (13) 1677; DOI: 10.1503/cmaj.050601
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Mimicking Alzheimer's disease
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Neurology

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire